WO2007013547A1 - 更年期障害予防・改善剤および機能性飲食品 - Google Patents
更年期障害予防・改善剤および機能性飲食品 Download PDFInfo
- Publication number
- WO2007013547A1 WO2007013547A1 PCT/JP2006/314863 JP2006314863W WO2007013547A1 WO 2007013547 A1 WO2007013547 A1 WO 2007013547A1 JP 2006314863 W JP2006314863 W JP 2006314863W WO 2007013547 A1 WO2007013547 A1 WO 2007013547A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lignan
- lactobacillus acidophilus
- estrogen
- lignans
- food
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Definitions
- the present invention relates to a preventive / improving agent for menopausal disorders and a functional food or drink for obtaining various preventive and ameliorating actions for various symptoms that develop with menopause.
- Menopause is a physical 'mental indefinite complaint caused by decreased secretion of female hormones (estrogens) from the ovaries before and after menopause. Later, with age, various symptoms such as skin aging, hyperlipidemia, osteoporosis, and brain function deterioration appear.
- HRT hormone replacement therapy
- WHI Wiman's Health Initiative
- Patent Document 1 Japanese Patent No. 3435415
- Non-patent literature l Ivon E.J.Milder et al.Br.J.Nutr., 93,393-402 (2005)
- Non-Patent Document 2 U-Hua Xie et al., Chem. Pharm. Bull. 51 (5), 508-515 (2003) Disclosure of the Invention Problems to be solved by the invention
- An object of the present invention is to provide a drug and a functional food or drink useful for preventing or improving climacteric disorder.
- Lactobacillus acidophilus can metabolize lignan to produce an estrogen-like active intermediate, thereby completing the present invention. That is, according to the present invention, there is provided a method for producing an estrogen-like active intermediate, which comprises culturing lignan together with Lactobacillus acidophilus.
- the lignan is pinoresinol or medoredinol.
- the redanan is a Tochu lignan.
- the estrogenic active intermediate is sequoisolarisiresinol.
- the present invention provides a menopausal prophylaxis ameliorating agent and a functional food and drink for preventing / improving climacteric dysfunction, which contain as an active ingredient a lignan cultured with Lactobacillus acidophilus.
- climacteric disorder By ingesting lignan cultured together with Lactobacillus acidophilus, or by simultaneously ingesting Lactobacillus acidophilus and lignan, climacteric disorder can be prevented or ameliorated.
- the climacteric disorder preventing / ameliorating agent of the present invention and the functional food and drink containing the same contain lignans already confirmed to be safe and taken orally, so that they can be safely taken orally.
- FIG. 1 shows an expected metabolic pathway of pinoresinol * didalcoside, a kind of lignan, by intestinal bacteria.
- the agent for preventing and improving climacteric disorder according to the present invention contains lignan that is metabolized and activated by culturing with Lactobacillus acidophilus as an active ingredient. It is higher than taking lignans before being activated.
- lignans include Tochu lignan, flaxseed lignan, sesame lignan and the like.
- the lignan is a Tochu lignan.
- Lignan is first converted to aglycone by Lactobacillus acidophilus.
- pinoresinol and medoredinol are metabolized by Lactobacillus acidophilus and converted into various estrogen-like active intermediates.
- an estrogen-like active intermediate means both a substance that itself has an estrogenic activity and a substance that is further metabolized in vivo and converted into a substance that has an estrogenic activity when ingested.
- Estrogenic activity intermediates include rasiliresinol and secoisolaricillinol.
- the estrogen-like active intermediate is secoisolaricillinol.
- an estrogen-like active intermediate is produced by being metabolized by lignancantobacillus acidophilus, and this estrogen-like active intermediate is actually used as an estrogen. It was found to have the ability to bind to the receptor.
- the strain of Lactobacillus acidophilus is not particularly limited.
- Lactobacillus acidophilus CL-0062 strain National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary, Deposit No. FERM BP) — 4980, date of deposit, March 4, 1994
- La Bacillus acidophilus L92 strain National Institute of Advanced Industrial Science and Technology patent product deposit center, deposit number FERM BP— 4981, date of deposit: March 4, 1994
- FERM BP National Institute of Advanced Industrial Science and Technology patent product deposit center
- Lactobacillus acidophilus CL-0062 strain has the following mycological properties.
- Lactobacillus acidophilus L92 strain has the following mycological properties.
- Lignan can easily obtain strengths such as sesame, flaxseed, and tanaka.
- a particularly preferred lignan is Tochu lignan.
- the Tochu lignan can be used by appropriately fractionating, concentrating and purifying the extract of Tochu's bark or leaves or the extract, and the extract and its concentrate can be obtained by freeze drying, spray drying, etc. It can also be used as a powder.
- the cells of Lactobacillus acidophilus are added to a medium containing lignans, and are usually left standing or stirred, for example, at a temperature of 25 ° C to 45 ° C. C, preferably 30 ° C to 45 ° C.
- Lignan can be added at a final concentration of 0.01-10 mM, for example in the form of a MeOH solution.
- Lactobacillus acidophilus cells pre-cultured at 37 ° C. for 20 to 24 hours in an MRS medium, GAM medium, milk medium or the like are preferably used as a starter.
- the initial bacterial count is preferably Is about 10 5 — 10 9 Zml.
- the culture time is 3 to 168 hours, preferably 12 to 96 hours.
- the culture can be stopped when the lactic acidity reaches 1.5 or higher.
- the aerobic Z anaerobic condition can be appropriately selected depending on the bacterial species used.
- a lignan metabolic intermediate obtained by culturing lignan with Lactobacillus acidophilus In order for a lignan metabolic intermediate obtained by culturing lignan with Lactobacillus acidophilus to exhibit estrogenic activity, binding of the metabolic intermediate to an estrogen receptor is essential.
- the estrogen receptor binding ability can be examined, for example, by evaluating the proliferation activity of MCF-7 cells or by performing an estrogen receptor assay using yeast.
- lignans cultured with Lactobacillus acidophilus were orally administered to a climacteric model animal from which the ovaries had been removed, and the bone density and blood cholesterol of the animal were examined. The effect can be confirmed using these as indicators.
- the agent for preventing and improving climacteric disorder of the present invention can be produced by preparing a lignan cultured with Lactobacillus acidophilus as a pharmaceutical preparation by a method known to those skilled in the art.
- lignans cultured with lactic acid bacteria are pharmaceutically acceptable carriers or media, specifically sterile water, physiological saline, vegetable oils, emulsifiers, suspensions, surfactants, stabilizers, flavoring agents, excipients It can be formulated by mixing with agents, vehicles, preservatives, binders, etc. in appropriate combinations.
- the 'menopausal disorder prevention' ameliorating agent of the present invention may contain other known components having an effect of improving 'menopausal disorder prevention' in addition to lignans cultured with lactic acid bacteria as active ingredients.
- the oral intake of the menopausal disorder prevention / ameliorating agent of the present invention can be appropriately selected so as to obtain a desired effect according to the administration period, continuity thereof, and the like. Dosage varies depending on age, body weight, symptoms, treatment effect, administration method, treatment time, etc. Normally, 1 adult can be administered orally once a day in the range of lmg to lOOOmg per person. it can. Since both lignans and lactic acid bacteria are edible, there is no restriction on the dosage for safety reasons.
- the menopausal disorder prevention / improving agent of the present invention may be administered after various symptoms associated with menopause have occurred, and continuously or intermittently at a time when such symptoms are prevented. In Please administer.
- a functional food or drink containing lignans cultured with lactic acid bacteria is provided.
- the blending ratio of the lignan cultured with lactic acid bacteria can be appropriately selected according to the form of the functional food / beverage product, continuity of intake, etc., and is not particularly limited.
- Examples of the functional foods and drinks include various processed foods and drinks, tea drinks, dry powders, tablets containing fermented milk products such as yogurt and lactic acid bacteria beverages, fermented milk whey, or concentrates thereof. , Capsules, granules and the like.
- Additives such as sugars, proteins, lipids, vitamins, minerals, flavors, or mixtures thereof may be added to the functional food and drink. It may also contain an extract of plant lignans.
- the functional food and drink of the present invention are foods and drinks containing the menopausal disorder prevention / improving agent of the present invention, and appealed for prevention and improvement of various symptoms associated with menopause, such as foods for specified health use, etc. It can be.
- the intake and timing of the functional food and drink of the present invention are not particularly limited. For example, before or after contact with a situation where an improvement effect is required for each symptom of climacteric disorder, it is continuous or intermittent. In addition, it can be taken continuously or intermittently after exposure to such a situation.
- the lignan metabolic capacity of various microorganisms was evaluated.
- the various microorganisms shown in Table 13 below are pre-cultured at 37 ° C for 20-24 hours using MRS medium or GAM medium. Inoculated at 13% in MRS medium or GAM medium.
- Tochu lignans pinoresinol and medoredinol were added so that the final concentration in the medium was 0.5 mM, and the culture was continued at 37 ° C. Sampling was performed over time, and the state in which the added lignan was metabolized and changed to secoysolarisirinol was quantitatively measured by HPLC.
- the lignans converted by more than 50% are shown as ⁇ , and the lignans converted almost as X.
- Table 13 The results are shown in Table 13.
- Lactobacillus acidophilus has the ability to produce secoisolarisiresinol from pinoresinol. Furthermore, it was shown that at least the Lactobacillus acidophilus strains measured this time have the ability to produce Medioredinol caseoisoralisiresinol. These results indicate that Lactobacillus acidophilus has the ability to metabolize lignans and convert them into estrogen-like active intermediates.
- ImM test sample (Pinoresinol 'Didalcoside, Pinoresinol, Secoisoralisiresinol) and 0.5nM tritium-labeled estradiol recombinantly containing human-type estrogen receptor ⁇ or / 3 ⁇ 7.4 10mM Tris buffer (0.1% BSA, 10% Glycerol, ImM containing DTT) was reacted at 25 degrees for 2 hours. After the reaction The amount of tritium-labeled estradiol bound to the receptor was measured according to a standard method.
- the present invention is useful for the prevention and / or improvement of climacteric disorder.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/989,521 US20090104167A1 (en) | 2005-07-29 | 2006-07-27 | Prophylactic/Ameliorating Agent for Menopausal Disorder and Functional Beverage/Food |
EP06781774A EP1911849A4 (en) | 2005-07-29 | 2006-07-27 | AGENT FOR PROPHYLAXIS / IMPROVEMENT OF DISORDERS OF MENOPAUSE AND BEVERAGE / FUNCTIONAL FOOD |
CN2006800321824A CN101253270B (zh) | 2005-07-29 | 2006-07-27 | 更年期障碍预防·改善剂及功能性饮食品 |
JP2007526889A JP4808715B2 (ja) | 2005-07-29 | 2006-07-27 | 更年期障害予防・改善剤および機能性飲食品 |
CA002617031A CA2617031A1 (en) | 2005-07-29 | 2006-07-27 | Prophylactic/ameliorating agent for menopausal disorder and functional beverage/food |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005221984 | 2005-07-29 | ||
JP2005-221984 | 2005-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007013547A1 true WO2007013547A1 (ja) | 2007-02-01 |
Family
ID=37683438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/314863 WO2007013547A1 (ja) | 2005-07-29 | 2006-07-27 | 更年期障害予防・改善剤および機能性飲食品 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090104167A1 (ja) |
EP (1) | EP1911849A4 (ja) |
JP (1) | JP4808715B2 (ja) |
CN (1) | CN101253270B (ja) |
CA (1) | CA2617031A1 (ja) |
WO (1) | WO2007013547A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012077012A (ja) * | 2010-09-30 | 2012-04-19 | Kobayashi Pharmaceutical Co Ltd | 骨密度増加剤及び抗更年期障害剤 |
KR20180018422A (ko) * | 2016-08-12 | 2018-02-21 | 한국식품연구원 | 락토바실러스 아시도필루스를 포함하는 갱년기 예방 또는 치료용 조성물 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2471544B1 (en) * | 2009-10-22 | 2016-05-25 | Kabushiki Kaisha Yakult Honsha | Lactobacillus casei for use in reducing risk of developing cancer |
CN102100684B (zh) * | 2009-12-18 | 2013-05-22 | 北京大学 | 开环异落叶松脂素在制备治疗抑郁症、焦虑症的药物中的应用 |
CN103301179B (zh) * | 2013-07-01 | 2015-04-15 | 欧阳冬生 | 杜仲木脂素提取物在制备用于防治高甘油三脂血症的药物中的应用 |
WO2018030837A1 (ko) * | 2016-08-12 | 2018-02-15 | 한국식품연구원 | 락토바실러스 아시도필루스를 포함하는 갱년기 예방 또는 치료용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3435415B2 (ja) | 1997-05-07 | 2003-08-11 | 小林製薬株式会社 | 抗高脂血症機能を持つ食品 |
WO2003075686A1 (fr) * | 2002-03-11 | 2003-09-18 | Suntory Limited | Procede de production de sdg et aliments et boissons le contenant |
JP2004051616A (ja) * | 2002-07-19 | 2004-02-19 | Shimada Fumitake | タイワンテイカカズラの抽出物の採取法及びその使用法 |
JP2005221984A (ja) | 2004-02-09 | 2005-08-18 | Ricoh Co Ltd | 光学素子、光偏向素子、光偏向装置、画像表示装置及び抵抗体形成方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920002102B1 (ko) * | 1989-12-28 | 1992-03-12 | 오뚜기식품 주식회사 | 생약재를 이용한 발효음료의 제조방법 |
JP4046389B2 (ja) * | 1997-09-04 | 2008-02-13 | 株式会社ヤクルト本社 | ビフィドバクテリウム・ブレーベ及びこれを用いた発酵豆乳 |
US20020192310A1 (en) * | 2001-02-02 | 2002-12-19 | Bland Jeffrey S. | Medical composition for managing hormone balance |
BR0313182A (pt) * | 2002-07-24 | 2007-07-24 | Childrens Hosp Medical Center | composições e produtos contendo equol enantiomérico |
AU2003286781B2 (en) * | 2002-10-29 | 2009-05-21 | Brigham Young University | Use of equol for treating androgen mediated diseases |
EP1471070A1 (en) * | 2003-04-22 | 2004-10-27 | Royal Schouten Group N.V. | Method for recovering a secondary plant metabolite |
-
2006
- 2006-07-27 US US11/989,521 patent/US20090104167A1/en not_active Abandoned
- 2006-07-27 CN CN2006800321824A patent/CN101253270B/zh not_active Expired - Fee Related
- 2006-07-27 EP EP06781774A patent/EP1911849A4/en not_active Withdrawn
- 2006-07-27 CA CA002617031A patent/CA2617031A1/en not_active Abandoned
- 2006-07-27 WO PCT/JP2006/314863 patent/WO2007013547A1/ja active Application Filing
- 2006-07-27 JP JP2007526889A patent/JP4808715B2/ja not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3435415B2 (ja) | 1997-05-07 | 2003-08-11 | 小林製薬株式会社 | 抗高脂血症機能を持つ食品 |
WO2003075686A1 (fr) * | 2002-03-11 | 2003-09-18 | Suntory Limited | Procede de production de sdg et aliments et boissons le contenant |
JP2004051616A (ja) * | 2002-07-19 | 2004-02-19 | Shimada Fumitake | タイワンテイカカズラの抽出物の採取法及びその使用法 |
JP2005221984A (ja) | 2004-02-09 | 2005-08-18 | Ricoh Co Ltd | 光学素子、光偏向素子、光偏向装置、画像表示装置及び抵抗体形成方法 |
Non-Patent Citations (13)
Title |
---|
BONORDEN M.J.L. ET AL.: "Consumption of Lactobacillus acidophilus and Bifidobacterium longum do not alter urinary equol excretion and plasma reproductive hormones in premenopausal women", EUROPEAN JOURNAL OF CLINICAL NUTRITION, vol. 58, no. 12, 2004, pages 1635 - 1642, XP003007754 * |
HAMASAKI K. ET AL.: "Lignan-rui no Chonai Saikin ni yoru Taisha II Seiyaku Tochu nado ni Fukumareru Lignan-rui no Taisha ni Tsuite", THE JAPANESE SOCIETY OF PHARMACOGNOSY DAI 50 KAI (2003 NEN) NENKAI KOEN YOSHISHU, 5 August 2003 (2003-08-05), pages 69, XP003007749 * |
HEINONEN S. ET AL.: "In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 49, no. 7, 2001, pages 3178 - 3186, XP003007751 * |
IVON E. J. MILDER ET AL., BR. J. NUTR., vol. 93, 2005, pages 393 - 402 |
IVON E. J. MILDER ET AL., J. NUTR., vol. 93, 2005, pages 393 - 402 |
LAHTINEN S. ET AL.: "Interactions between Lignans and Probiotics", MICROBIOL ECOLOGY IN HEALTH AND DISEASE, vol. 14, no. 2, 2002, pages 106 - 109, XP003007753 * |
LI-HUA XIE ET AL., CHEM. PHARM. BULL., vol. 51, no. 5, 2003, pages 508 - 515 |
NETTLETON J.A. ET AL.: "Plasma phytoestrogens are not altered by probiotic consumption in postmenopausal women with and without a history of breast cancer", THE JOURNAL OF NUTRITION, vol. 134, no. 8, 2004, pages 1998 - 2003, XP003007752 * |
See also references of EP1911849A4 * |
THOMPSON L.U. ET AL.: "Mammalian lignan production from various foods", NUTRITION AND CANCER, vol. 16, no. 1, 1991, pages 43 - 52, XP000981449 * |
WANG L.-Q. ET AL.: "Human intestinal bacteria capable of transforming secoisolariciresinol diglucoside to mammalian lignans, enterodiol and enterolactone", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 48, no. 11, 2000, pages 1606 - 1610, XP008067420 * |
WHI (WOMAN'S HEALTH INITIATIVE, July 2002 (2002-07-01) |
XIE L.-H. ET AL.: "Biotransformation of pinoresinol diglucoside to mammalian lignans by human intestinal microflora, and isolation of Enterococcus faecalis strain PDG-1 responsible for the transformation of (+)-pinoresinol to (+)-lariciresinol", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 51, no. 5, 2003, pages 508 - 515, XP003007750 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012077012A (ja) * | 2010-09-30 | 2012-04-19 | Kobayashi Pharmaceutical Co Ltd | 骨密度増加剤及び抗更年期障害剤 |
KR20180018422A (ko) * | 2016-08-12 | 2018-02-21 | 한국식품연구원 | 락토바실러스 아시도필루스를 포함하는 갱년기 예방 또는 치료용 조성물 |
KR101867768B1 (ko) | 2016-08-12 | 2018-06-15 | 한국식품연구원 | 락토바실러스 아시도필루스를 포함하는 갱년기 예방 또는 치료용 조성물 |
JP2019524138A (ja) * | 2016-08-12 | 2019-09-05 | コリア フード リサーチ インスティテュート | ラクトバチルス・アシドフィルスを含む更年期の予防または治療用組成物 |
US11260087B2 (en) | 2016-08-12 | 2022-03-01 | Korea Food Research Institute | Composition for preventing or treating menopause, containing Lactobacillus acidophilus |
Also Published As
Publication number | Publication date |
---|---|
JP4808715B2 (ja) | 2011-11-02 |
EP1911849A4 (en) | 2012-01-11 |
CN101253270A (zh) | 2008-08-27 |
JPWO2007013547A1 (ja) | 2009-02-12 |
US20090104167A1 (en) | 2009-04-23 |
EP1911849A1 (en) | 2008-04-16 |
CA2617031A1 (en) | 2007-02-01 |
CN101253270B (zh) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200255795A1 (en) | Method for preparing microbial preparation and microbial preparation produced by the same | |
JP5030790B2 (ja) | エクオール含有大豆胚軸発酵物、及びその製造方法 | |
TW580517B (en) | Isoflavone-containing composition | |
DK2478910T3 (en) | ANTI-ADIPOSITY AGENT, ANTI-ADIPOSITA NUTRITION OR DRINK, GLUCOSE TOLERANCE EFFECTIVE AGENT, AND NUTRITION OR DRINK FOR IMPROVING GLUCOSE TOLERANCE | |
EP2546330B1 (en) | Lactic acid bacterium-containing preparation | |
Shilpa et al. | Biofunctionality of probiotic soy yoghurt | |
JP6479768B2 (ja) | 新規ラクトバチラス・パラカゼイ株 | |
WO2010098131A1 (ja) | 肥満予防又は改善剤 | |
KR20120034482A (ko) | 지방세포 분화 유도에 관여하는 유전자의 발현을 억제함으로써 지방세포 분화 억제 효능을 갖는 락토바실러스 플란타룸 케이와이1032 및 이를 유효성분으로 함유하는 제품 | |
CN117487683A (zh) | 具有抗幽护胃和消食化积功效的益生菌组合物及其应用 | |
JP4808715B2 (ja) | 更年期障害予防・改善剤および機能性飲食品 | |
KR102543494B1 (ko) | 신규 프로바이오틱스 및 이의 용도 | |
WO2002032441A1 (fr) | Agent ameliorant le metabolisme osseux | |
KR101266328B1 (ko) | 지방세포 분화 유도에 관여하는 유전자의 발현을 억제함으로써 지방세포 분화 억제 효능을 갖는 락토바실러스 가세리 에이치와이7021 및 이를 유효성분으로 함유하는 제품 | |
CN102742654B (zh) | 一种养颜美容益生菌羊奶片及其制备方法 | |
EP2935600A2 (en) | Process for producing conjugated linolenic acid from linolenic acid employing bifidobacterium breve, bifidobacterium bifidum, or lactobacillus oris strains | |
Lopes et al. | The importance of microbial and enzymatic bioconversions of isoflavones in bioactive compounds | |
KR101543509B1 (ko) | 금은화 발효물을 유효성분으로 함유하는 비만, 내독소혈증 또는 대사성 질환의 예방 또는 치료용 조성물 | |
TW201707566A (zh) | 一種具有抗氧化/消除自由基能力之黑蒜頭發酵乳及其製造方法 | |
JP7008435B2 (ja) | 小腸の腸内環境改善剤 | |
JP7402629B2 (ja) | プロピオン酸菌発酵物含有組成物 | |
KR102514059B1 (ko) | 체내흡수율이 증가된 엘라그산과 갈산을 고함량 포함하는 뼈건강 또는 여성갱년기 증상 개선용 석류 발효조성물 및 efc 공법을 이용한 그의 제조방법 | |
KR102434006B1 (ko) | 항비만 활성을 갖는 유산균을 함유하는 식품 조성물 | |
TW202237815A (zh) | 一種含副乾酪乳酸桿菌s38和凝結芽孢桿菌bc198之益生菌組合物及其在改變身體組成之應用 | |
CN117356711A (zh) | 一种具有改善胆汁酸代谢功能的合生元及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680032182.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007526889 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2617031 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006781774 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11989521 Country of ref document: US |